Jul 2026· International Journal of Drug Delivery Technology· Vol 16· 0 citations· 30 references
TL;DR
The study highlights the biphasic biological behavior of p-cymene, characterized by non-toxic or mildly stimulatory effects at low concentrations and pronounced cytotoxicity at higher doses.
Abstract
Natural bioactive compounds continue to attract scientific attention due to their safety, accessibility, and broad
therapeutic potential. Among these, monoterpenes present in essential oils have shown promising pharmacological
activities, including neuroprotective effects. The present study aimed to evaluate the neuroprotective potential of pcymene, a widely distributed monoterpene, using in silico molecular docking and in vitro neuroprotective assessment
in SH-SY5Y cells. Molecular docking was performed using AutoDock against selected target proteins to understand
binding affinity and interaction patterns. The docked phytochemicals exhibited binding energies ranging from −6.4 to
−9.6 kcal/mol, indicating favorable interactions primarily mediated through van der Waals and alkyl forces, suggesting
potential modulation of protein activity through non-covalent interactions. For experimental validation,
neuroprotection was assessed using the MTT assay in SH-SY5Y cells exposed to increasing concentrations of pcymene (1–10 mg/mL). The results demonstrated a clear dose-dependent response. Lower concentrations to medium
concentrations (1 and 7 mg/mL) showed increased cell viability compared to control, indicating possible enhancement
of mitochondrial activity or adaptive cellular responses. However, a slight decline in cell viability was observed at
higher concentrations, with slightly lesser neuroprotective effects at 10 mg/ml. Overall, the study highlights the
biphasic biological behavior of p-cymene, characterized by non-toxic or mildly stimulatory effects at low
concentrations and pronounced cytotoxicity at higher doses. These findings support the potential of p-cymene as a
bioactive compound with concentration-dependent therapeutic relevance, warranting further mechanistic and
preclinical investigations
Findings highlight D. gangeticum as a promising source of bioactive compounds with significant anticancer potential, warranting further mechanistic and preclinical investigations.
Baably Swayamsidha, Shubhranshee Sanshlishta Sahu, A. Pattnaik et al.· In Silico Pharmacology· 0 citations
INTRODUCTION
Cognitive impairment, also commonly referred to as intellectual disability, is a complex disorder that affects a person's ability to think, remember, and learn. Bisphenol A is an environmental toxicant that has detrimental effects on the nervous system's functioning over prolonged periods. Bioactive phytoc...
Sagarika Majhi, Prashant Sharma, H. Tyagi et al.· Current Computer - Aided Dru...· 0 citations
The studies showed that the CNR2 is a promising scaffold with potent antioxidant and anti-inflammatory properties however with moderate antidiabetic potency.
Pritesh P. Khobrekar, Vilas K. Gawade, D. Barretto et al.· Discover Chemistry· 0 citations
ABSTRACT Medicinal plants are valuable sources of bioactive compounds with potential applications in neurodegenerative disorders. This study investigated the antioxidant, neuropharmacological, and monoamine oxidase (MAO) inhibitory activities of Ligustrum sinense (L. sinense) leaf extract through in vitro, in vivo, and...
Sowmitro Das, S. M. Istiaque Hamim, Md. Nazmul Hasan Zilani et al.· Chemistry and Biodiversity· 0 citations
This in silico study evaluated 12 bioactive compounds from an ethanolic extract of M. oleifera as potential inhibitors of this molecular target and identified quercetin, apigetrin, chlorogenic acid, ellagic acid, and naringenin as the most promising candidates.
Putri Sabilla, T. Sari· Journal multidisciplinary sc...· 0 citations
Neurodegenerative disorders such as Alzheimer’s disease (AD) and Parkinson’s
disease (PD) are driven by oxidative stress, neurotransmitter imbalance, and protein aggregation,
leading to progressive neuronal loss. Both plant extracts represent promising phytopharmacological
sources with multitarget neuroprotective p...
Christopher Rejitha, L. Babu· Current Enzyme Inhibition· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.